Understand the source comparison
ARA-290 FAQ: Dosing, Routes, Storage Comparison
This table synthesizes the most frequently referenced parameters from published ARA-290 research protocols across neuroprotection, tissue repair, and inflammatory injury models. Dose Range 10–300 μg/kg depending on model 30–100 μg/kg twice daily for most endpo
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table synthesizes the most frequently referenced parameters from published ARA-290 research protocols across neuroprotection, tissue repair, and inflammatory injury models.
- Dose Range
- 10–300 μg/kg depending on model
- 30–100 μg/kg twice daily for most endpoints
- Doses above 100 μg/kg rarely produce additional benefit due to receptor saturation; start at 30–50 μg/kg and escalate only if pilot data justify it
- Administration Route
- SC, IP, IV, or continuous infusion
- SC injection for simplicity and reproducibility
- Subcutaneous achieves 60–70% bioavailability with minimal technique-dependent variability; IV adds complexity without proportional benefit for tissue-protective endpoints
- Dosing Frequency
- Once daily to continuous infusion
- Twice daily for bolus protocols
- Plasma half-life of 4–6 hours means once-daily dosing produces suboptimal receptor occupancy; twice-daily maintains more consistent signaling
- Reconstitution Fluid
- Bacteriostatic water or sterile saline
- Bacteriostatic water for multi-use vials
- Bacteriostatic water (0.9% benzyl alcohol) inhibits microbial growth; use sterile saline only for single-use immediate administration
- Storage (Lyophilised)
- −20°C to −80°C
- −20°C for typical lab freezers
- Stability exceeds 24 months at −20°C; −80°C offers no practical advantage for storage durations under 36 months
- Storage (Reconstituted)
- 2–8°C for up to 28 days
- Use within 14 days when possible
- Peptide aggregation accelerates beyond 14 days even under refrigeration; aliquot and freeze if longer timelines required